121850 AGL 2263
AGL 2263 MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
Synonyms: AG 2263
This product has been discontinued.
We apologize for the inconvenience, but we do not currently have an alternative product. Please refer to our complete listing of receptor tyrosine kinase inhibitors for possible alternatives. Please read the alternative product documentation carefully and contact technical service if you need additional information.
A cell-permeable benzoxazolone-containing bioisostere of tyrphostin AG 538 (Cat. No. 658403) that acts as a potent, substrate-competitive, but not ATP-competitive, inhibitor of insulin receptor (IR) and insulin-like growth factor-1 receptor (IGF-1R). It is selective towards IR and IGF-1R (IC50 = 0.4 and 0.43 µM, respectively) and inhibits Src and PKB only at much higher concentrations (IC50 = 2.2 and 55 µM, respectively) in kinase assays. Shown to prevent IGF-1-induced cellular IGF-1R autophosphorylation and down stream signalling. Specifically inhibits IGF-1-induced, but not PDGF-induced, activation of PKB in cells. Effectively blocks the formation of colonies in soft agar by breast and prostate cancer cells. Exhibits improved cellular oxidative stability than AG 538.
|References||Blum, G., et al. 2003. J. Biol. Chem. 278, 40442.|
|Structure formula Image|
|Primary Target IC<sub>50</sub>||0.43 µM|
|Secondary target||IR (IC₅₀ = 0.4 µM) and inhibits Src and PKB at (IC₅₀ = 2.2 and 55 µM, respectively)|
|Purity||≥97% by HPLC|
|Safety Information according to GHS|
|Product Usage Statements|
|Packaged under inert gas||Packaged under inert gas|
AGL 2263 Certificates of Analysis
|Blum, G., et al. 2003. J. Biol. Chem. 278, 40442.|